Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, a...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-82762-8 |
| _version_ | 1818427513110528000 |
|---|---|
| author | Nicolas Nagot Mandisa Singata-Madliki Amandine Cournil Joyce Nalugya Souleymane Tassembedo Catherine Quillet Melany W. Tonga James Tumwine Nicolas Meda Chipepo Kankasa Mwiya Mwiya Paul Bangirana Marianne Peries Joanne Batting Ingunn M. S. Engebretsen Thorkild Tylleskär Philippe Vande Perre Grace Ndeezi Jean-Pierre Molès |
| author_facet | Nicolas Nagot Mandisa Singata-Madliki Amandine Cournil Joyce Nalugya Souleymane Tassembedo Catherine Quillet Melany W. Tonga James Tumwine Nicolas Meda Chipepo Kankasa Mwiya Mwiya Paul Bangirana Marianne Peries Joanne Batting Ingunn M. S. Engebretsen Thorkild Tylleskär Philippe Vande Perre Grace Ndeezi Jean-Pierre Molès |
| author_sort | Nicolas Nagot |
| collection | DOAJ |
| description | Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. Between February 2017 and February 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not HIV-infected. In addition to clinical examination, neuropsychological outcomes were assessed using the tests Kaufman-ABCII, Test of Variables of Attention, Movement Assessment Battery for Children and the Strengths and Difficulties questionnaire, parent version. Of 1101 eligible children, aged 5–7 years, 553 could be traced and analysed (274 in the LPV/r and 279 in the 3TC groups). Growth, clinical and neuropsychological outcomes did not differ between treatment groups. At school age, children exposed to LPV/r and 3TC at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral drug in early life. |
| first_indexed | 2024-12-14T14:46:55Z |
| format | Article |
| id | doaj.art-3c2f1f5d320041d796767d8a985af567 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-14T14:46:55Z |
| publishDate | 2021-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-3c2f1f5d320041d796767d8a985af5672022-12-21T22:57:15ZengNature PortfolioScientific Reports2045-23222021-02-0111111010.1038/s41598-021-82762-8Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early lifeNicolas Nagot0Mandisa Singata-Madliki1Amandine Cournil2Joyce Nalugya3Souleymane Tassembedo4Catherine Quillet5Melany W. Tonga6James Tumwine7Nicolas Meda8Chipepo Kankasa9Mwiya Mwiya10Paul Bangirana11Marianne Peries12Joanne Batting13Ingunn M. S. Engebretsen14Thorkild Tylleskär15Philippe Vande Perre16Grace Ndeezi17Jean-Pierre Molès18Pathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, Université de Montpellier, Etablissement Français du Sang, Université des AntillesUniversity of Fort HarePathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, Université de Montpellier, Etablissement Français du Sang, Université des AntillesSchool of Medicine, College of Health Sciences, Makerere UniversityCentre MURAZPathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, Université de Montpellier, Etablissement Français du Sang, Université des AntillesDepartment of Paediatrics and Child Health, University Teaching HospitalSchool of Medicine, College of Health Sciences, Makerere UniversityCentre MURAZDepartment of Paediatrics and Child Health, University Teaching HospitalDepartment of Paediatrics and Child Health, University Teaching HospitalSchool of Medicine, College of Health Sciences, Makerere UniversityPathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, Université de Montpellier, Etablissement Français du Sang, Université des AntillesUniversity of Fort HareCentre for International Health, University of BergenCentre for International Health, University of BergenPathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, Université de Montpellier, Etablissement Français du Sang, Université des AntillesSchool of Medicine, College of Health Sciences, Makerere UniversityPathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, Université de Montpellier, Etablissement Français du Sang, Université des AntillesAbstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. Between February 2017 and February 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not HIV-infected. In addition to clinical examination, neuropsychological outcomes were assessed using the tests Kaufman-ABCII, Test of Variables of Attention, Movement Assessment Battery for Children and the Strengths and Difficulties questionnaire, parent version. Of 1101 eligible children, aged 5–7 years, 553 could be traced and analysed (274 in the LPV/r and 279 in the 3TC groups). Growth, clinical and neuropsychological outcomes did not differ between treatment groups. At school age, children exposed to LPV/r and 3TC at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral drug in early life.https://doi.org/10.1038/s41598-021-82762-8 |
| spellingShingle | Nicolas Nagot Mandisa Singata-Madliki Amandine Cournil Joyce Nalugya Souleymane Tassembedo Catherine Quillet Melany W. Tonga James Tumwine Nicolas Meda Chipepo Kankasa Mwiya Mwiya Paul Bangirana Marianne Peries Joanne Batting Ingunn M. S. Engebretsen Thorkild Tylleskär Philippe Vande Perre Grace Ndeezi Jean-Pierre Molès Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life Scientific Reports |
| title | Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life |
| title_full | Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life |
| title_fullStr | Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life |
| title_full_unstemmed | Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life |
| title_short | Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life |
| title_sort | growth clinical and neurodevelopmental outcomes at school age are similar for children who received 1 year lamivudine or lopinavir ritonavir hiv prophylaxis in early life |
| url | https://doi.org/10.1038/s41598-021-82762-8 |
| work_keys_str_mv | AT nicolasnagot growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT mandisasingatamadliki growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT amandinecournil growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT joycenalugya growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT souleymanetassembedo growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT catherinequillet growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT melanywtonga growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT jamestumwine growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT nicolasmeda growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT chipepokankasa growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT mwiyamwiya growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT paulbangirana growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT marianneperies growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT joannebatting growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT ingunnmsengebretsen growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT thorkildtylleskar growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT philippevandeperre growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT gracendeezi growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT jeanpierremoles growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife |